A sensitive high-performance liquid chromatographlc (HPLC) assay using fluorescence detection for quantifying hdocame levels m plasma (m the ng/ml range) was developed This novel HPLC assay has made possible the simultaneous momtormg of hdocame levels m coronary and peripheral plasma obtained after myocardlal controlled-release matrix admmlstratlon (0 92 mg/kg durmg 4 h) m the arrhythmlc dog The method employed extracts the drug from plasma using 1-chlorobutane and a subsequent derlvatlzatlon with 9-fluorenylmethylchloroformate m acetomtnle at 110°C The derivative was chromatographed on a C,, reversed-phase column and measured with fluorescence detection (excitation 254 nm, emlsslon 313 nm) N-Methylephedrme was found to be suitable as an internal standard, post-denvatlzatlon The derlvatlzatlon product of hdocame was identified and characterized by mass spectral analysis It was found to have a unique and reproducible dlcarbamate structure, which was stable for at least three days at room temperature The method was tested with human plasma as well as on dog plasma Analytical recoveries were 88 6 t 3 6 and 77 4 + 3 0% (mean + S E ), respectively, at levels rangmg from 25 to 200 ng/ml The lower detectlon hmlt was 1 ng/ml hdocame In conclusion, this rapid and 
INTRODUCTION
Lrdocaine (Z-diethylammo-2',6'-acetoxyhdlde) has been widely employed mtravenously in the treatment of ventricular arrhythmias [ 1,221 High-performance liquid chromatographic (HPLC) analysis offers a convenient and routme methodology for lidocame momtormg (see, e.g., refs. 3-8) . Thus far, there has not been any need for a particularly sensitive method to monitor plasma hdocame levels during therapy. The reason for this has been the high therapeutic range of lidocaine levels in plasma (1.5-6 mg/l) followmg intravenous adnnnistratlon [9, 10] , which is easily quantitated using UV detection.
During our mvestlgatlons of the &e-specific treatment of experimental ventricular tachycardia (VT) m dogs by usmg epicardial controlled-release hdocame, exceedingly low doses of drug were effective (300-400 fig/kg during 4 h of admunstration) to convert VT to sinus rhythm [ 11, 121 In these studies the systemic plasma hdocame levels were undetectable with HPLC and UV detection methodology [ 
121.
In order to conduct pharmacokmetic studies usmg epmar&al admmistration, a more sensitive method for monitoring lidocame in plasma needed to be developed. In addition, our particular experlmental application required analysis on relatively small volumes of blood samples (0 3-0.5 ml), mainly because of the limited amount of blood that can rapidly be obtained from the coronary blood vessels
In this paper we describe a new sensitive fluorescence HPLC assay for the routine quantitative determmatlon of lidocaine m plasma. We have used a new chloroformate reagent (9-fluorenylmethylchloroformate, 9-FMClF), which has recently been used as an amino-protective group in peptlde synthesis [ 13,141 and as a derlvatlzing agent reacting with the pipernlme moiety of pirlimycin [ 151. The obJectives of this paper were (a) to develop a more sensitive assay for momtormg coronary plasma levels of lidocame, (b) to examine the m vlvo applicabdity of this assay m pharmacokmetm studies in dogs treated with cardiac controlled-release hdocaine, and (c ) to determine if this methodology could be applicable to human plasma samples.
EXPERIMENTAL

Chemrcals
Lldocame hydrochloride was provided by Abbott Labs. (Chicago, IL, U S A.) Lldocame free base was obtamed from Sigma (St. Louis, MO, U S A ) Ethylmethylglycylxyhdlde (EMGX) was obtained from Astra (Worcester, MA, U S.A.). lR,2R-( fl-N-Methyl-4-ephedrine (NME) was obtained from Sigma. Stock solutions of lidocaine hydrochloride and NME in water were prepared at concentrations of 1 and 10 M/ml, respectively. Stock solutions of lidocame free base and NME in anhydrous acetonitrile were also prepared. 9-FMClF was obtained from Aldrich (Milwaukee, WI, U.S.A.). Anhydrous potassium carbonate was purchased from J.T. Baker (Phillipsburg, NJ, U.S.A.). 1-Chlorobutane (Aldrich), acetonitrile (J.T. Baker), and triethylamine (J.T. Baker) were all HPLC grade. Acetomtrile used for derivatization was dried over molecular sieves (Type 4A, 8-12 mesh, pore size 4A; Fisher Scientific, Fair Lawn, NJ, U.S.A. ).
A polyurethane two-component system (Tecoflex 2-BOA, Thermedics, Woburn, MA, U.S.A.) was used for preparing the controlled-release matrices, and ferric chloride (Fisher) was used as a catalyst in the polymerization [ 111.
Canme plasma was obtained during the course of dog experiments concerned with controlled-release lidocaine administration [ 121. Freshly obtained dog plasma obtained both prior to and after lidocaine admimstration was stored at -20" C Fresh frozen human plasma obtained from subjects who were not receiving lidocaine was provided by the University of Michigan Blood Bank.
Apparatus
Liquid chromatographic analyses were performed on a Waters Model 501 (Waters, Milford, MA, U.S.A.) lugh-performance liquid chromatograph, winch was equipped with a prepared C,, column (Waters pBondapakTM C1s, 15 cm x 3.9 mm I.D., particle size 10 pm). The column temperature was maintained at 30 ' C with a column heater and temperature control modules (Waters ) The detection of the lidocame derivative was carried out with a Waters 420 fluorescence detector. A combination of a 254-nm-bandpass excitation filter, a 313-nm-bandpass emission filter, and a mercury source lamp G4T5 (Waters filters kit ) was used. Data was recorded on a Waters 740 Data Module single-channel integrator.
Sample preparatron
Ertractmz Aliquots (0.5-1.0 ml) of dog or human plasma (non-hdocainecontaining) were spiked with appropriate amounts of lidocaine aqueous solution (1 pm/ml), followed by the addtlon of 50 ~1 of internal standard solution (10 pg/ml), 0.2 ml of 1 M sodium hydroxide, and 3 ml of 1-chlorobutane. Sodmm hydroxide was used in order to convert lidocaine hydrochloride to its free base, which can be extracted mto the organic phase and reacted with 9-FMClF. After vortexing, the organic layer was separated The organic layer was next evaporated to dryness under vacuum and the residue derivatlzed.
Dercvatzzatlon The dried residues in 5-ml tubes were redissolved in 0.4 ml of anhydrous acetomtrile followed by an addition of 50 ~1 saturated solution of potassium carbonate in acetonitrile. A 50-~1 volume of a freshly prepared solution of 9-FMClF reagent m acetomtrile (1 mg/ml) was then added The mixtures were vortexed and incubated in open tubes at 110 o C for 60 min. The tubes were allowed to cool and the resrdues were redssolved in 0.1 ml of acetonitrile. Samples of 20 ,~l were injected into the HPLC system.
Hgh-performance lqud chromatography
Plasma samples were analyzed usmg an isocratic mobile phase consisting of an aqueous 0.02% acetic acid solution adjusted to pH 6.8 with triethylamme and combined m a 40 60 ratio with acetomtnle. A flow-rate of 2 ml/mm was used. Fluorescence detection was carried out with excitatron and emrsslon filters of 254 and 313 nm, respectively. The data were analyzed using a sevenpoint calibration curve which was run for every series of chromatographed samples
Recovery
Various aliquots of hdocame hydrochloride solution (1 pg/ml) were mixed with 1 ml of drug-free plasma and the samples were analyzed according to the extraction procedure described above. For these analyses, the internal standard solution in anhydrous acetonitrlle was added after the extraction was terminated. A series of external standards was prepared by adding the same amounts of internal standard solution to a set of vamous ahquots of lidocaine free base solution ( 1 pg/ml ) (see Chemicals) . Prior to the determination of lidocaine by HPLC, the solutions were concentrated to dryness under vacuum (at 55 o C ) and derivatlzed as described above. AnalytIcal recoveries were calculated by comparing peak-area ratios of the extracted standards to a calibration graph constructed for hdocaine base from the external standards' set.
Precxsslon
Four aliquots (10 ml) of canme and human plasma were spiked with the appropriate amounts of hdocame hydrochloride to achieve concentrations of 50,100,150, and 200 ng/ml and were then stored at -20" C for two weeks On different days, l-ml samples were taken from the various stored ahquots and analyzed. The data were compared with a fresh calibration curve which was constructed from standard samples extracted on the same day.
Syntheses of the 9-fluorenylmethyloxycarbonyl derwakue of hdocarne
Lidocaine base or EMGX, which differs from lidocaine by the substitution of one ethyl by a methyl group (0.002 mol) was dissolved in 5 ml of a saturated solutron of potassium carbonate in anhydrous acetomtrlle. 9-FMClF (0.006 mol) was added, and the solution was mixed and placed m an oven at 110' C. Samples of 1 fl were taken periodically and spotted on a thm-layer chromatography (TLC) plate (precoated silica gel 60, layer thickness 0 2 mm, E. Merck, Darmstadt, F.R.G.) and were subsequently developed with hexaneethyl acetate-methylene chloride (60 20 20). Using short-wavelength UV detection, the reaction progress was traced until completion after 6 h. Portions of the solution were then taken on preparative TLC plates (precoated silica gel 60, layer thickness 2 mm) and chromatographed using the same development described above. After separation, silica bands were scraped from the plate, extracted with acetonitrlle, and filtered. The acetonitrile was evaporated and the residual oil was identified by mass spectral analysis, using a fast atom bombardment instrument (VG Analytical 70-2508, Manchester, U.K. ).
Controlled-release m&m and experrmental ventrzcular tachycardra
Lidocaine hydrochloride matrices were formulated as 28% dispersions in a reactive mixture of Tecoflex 80A polyurethane according to a previously related technique [ 111. In an open-chest dog (male mongrel, 20 kg) preparation, VT was induced by rapid ventricular pacing [ 121 at a cycle length of 50 ms using the methodology of Toda et al. [ 161. After the induction of VT, a lidocame hydrochloride-polyurethane matrix (5 mm~5 mm, 44 mg) was placed adlacent to the stimulating electrode. During m viva controlled release and eventual conversion of the VT to sinus rhythm, blood samples were taken slmultaneously from the coronary vem (0.3-0.5 ml per sample) and from the femoral artery (5 ml) through indwelling catheters
RESULTS AND DISCUSSION
Charactematwn of chloroformate reactron and ldocarne derrvatwes
Carbamates derived from tertiary amines have been already used in gas chromatography In contrast to the above publications we found that, under the conditions described in this report, the tertiary amine moiety of hdocaine reacts with two equivalents of the chloroformate (9-FMCIF) , resulting m a stable ionic form of dicarbamate (Fig. 1) . This compound was stable at room temperature for at least three days, based on repeating HPLC analyses. Only one ethyl group in both, lidocaine and EMGX, was degraded (Fig. 1 ) , suggestmg two important findings: (a) the tendency to cause nitrogen-alkyl (N-R) cleavage favoured the ethyl group over the methyl group, and this is m contrast to the finding of Kometani et al. [ 271, (b) the elimination of the other alkyl group, due to the EvaEuat~on of the anulytacalprocedure Typical chromatograms of the derivatives of lidocame and NME from plasma extracts are presented m Fig. 2 . Under the assay condklons used, reproducible retention times of 14 8 and 11.5 mm were obtained for hdocaine and N-methylephedrme, respectively. There was no interference from endogenous plasma compounds. Plots of the calibration curves of plasma hdocame [peak-area ratio of drug to its respective internal standard (y) versus drug concentration (x) ] over the range 25-500 ng/ml were linear The linear regression equation wasy=O.O12x (r=O 999) for dogplasmaandy=O.Ollx (r=0.981) for human plasma The lower limit of detection was 1 ng per 1nJectlon.
1-Chlorobutane was used m this assay as the extraction solvent and was shown to be very efficient (about 80% hdocame recovery from dog and human plasma and virtually no interfering compounds detected on HPLC) Chromatographlc experiments were performed using both C18 (5 and 10 pm particle size) reversed-phase columns and cyano-bonded phase columns with varrous mobile phase compositions. The optimum resolution for the plasma extracts was achieved by using a C,, reversed-phase column (10 pm particle size). Trlethylamme was found to be an essential component m the mobile phase m achieving narrow peaks and in eliminating interfering tailing peaks, which appeared sometimes in plasma extracts.
Assay valrdatron
The extraction efficiency or the recovery of lidocaine hydrochloride was determined as described in the Experimental section. Table I shows the recoveries in various hdocame plasma levels; the average extraction efficiencies were 77.4 + 3.0 and 88.6 2 3.6% from dog and human plasma, respectively Assay precision was established by performing seven replicate analyses of four control samples contanung 50, 100, 150, and 200 ng/ml hdocaine on different days during a two-week period. The replicate samples were extracted, derivatized, and chromatographed as described in the Experimental section. The results are shown m Table II The observed values of the various levels of hdocame as measured chromatographlcahy were not sqquficantly different from the actual concentrations (Table II) Applrcabdtty of the assay to blologxal studres The biomedical apphcation and the utihty of the HPLC method was demonstrated by a pharmacokmetm study performed with controlled-release hdocame matrices In this study a hdocame-polyurethane matrix [ 28% (w/w), 44 mg, 5 mmX 5 mm] was placed on the left ventricular epicardium adJacent to a pacing electrode m order to convert experimental VT m a dog model to sinus rhythm as previously described [ 121. As shown m Fig 3, the regional coronary venous plasma levels of hdocame were in the range 0 8-2.3 ,ug/ml while simultaneous peripheral blood levels were about lOO-fold lower (5.4-20.3 ng/ml). These findings emphasize the site-specificity of this admmistratlon, the prolonged action of the device, and suggest that the controlled-release lidocame may be an alternative to high systemic drug exposure which may be associated with adverse effects.
An additional series of experiments were carried out in an attempt to derivatize the principal metabolite of lidocaine, monoethylglycylxylidide (MEGX) with 9-FMClF, and achieve an HPLC separation using the conditions described above. However, an inadequate yield of the product was obtained and plasma concentrations of MEGX less than 200 ng/ml could not be detected.
In conclusion the HPLC method described is relatively simple and has an adequate sensitivity and precision to be used for pharmacokinetic studies following a low dose of controlled-release lidocaine. This rapid fluorometric method for assaying ng/ml levels of lidocaine should prove to be especially useful for studies of controlled-release hdocame admmistered directly to the heart
